Kura Oncology to Participate in Three Upcoming Investor Conferences
19 févr. 2020 16h05 HE
|
Kura Oncology, Inc.
SAN DIEGO, Feb. 19, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of...
Kura Oncology to Report Fourth Quarter and Full Year 2019 Financial Results
18 févr. 2020 16h05 HE
|
Kura Oncology, Inc.
SAN DIEGO, Feb. 18, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of...
Kura Oncology Announces Transition of Chief Medical Officer
23 janv. 2020 16h05 HE
|
Kura Oncology, Inc.
– Dr. Antonio Gualberto to step down after enabling multiple registrational strategies for tipifarnib, positioning program for success – – Clinical development, regulatory and medical affairs veteran...
Kura Oncology to Present at J.P. Morgan Healthcare Conference
09 janv. 2020 07h30 HE
|
Kura Oncology, Inc.
SAN DIEGO, Jan. 09, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of...
Kura Oncology Appoints Kirsten Flowers as Chief Commercial Officer
06 janv. 2020 07h30 HE
|
Kura Oncology, Inc.
SAN DIEGO, Jan. 06, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of...
Kura Oncology Receives Fast Track Designation for Tipifarnib in HRAS Mutant HNSCC and Provides Enrollment Guidance for AIM-HN Trial
16 déc. 2019 07h30 HE
|
Kura Oncology, Inc.
– Fast Track designation highlights potential for tipifarnib to address unmet need for patients with HRAS mutant HNSCC – – Registration-directed AIM-HN trial expected to complete enrollment in first...
Kura Oncology to Participate in Piper Jaffray Healthcare Conference
26 nov. 2019 07h30 HE
|
Kura Oncology, Inc.
SAN DIEGO, Nov. 26, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Kura Oncology to Present at Stifel Healthcare Conference
12 nov. 2019 07h30 HE
|
Kura Oncology, Inc.
SAN DIEGO, Nov. 12, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Kura Oncology Announces Upcoming Presentation at ASH Annual Meeting
06 nov. 2019 09h06 HE
|
Kura Oncology, Inc.
SAN DIEGO, Nov. 06, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of...
Kura Oncology Reports Third Quarter 2019 Financial Results and Provides Corporate Update
05 nov. 2019 16h05 HE
|
Kura Oncology, Inc.
– Updated data from Phase 2 trial of tipifarnib in HRAS mutant HNSCC support enrichment strategy in ongoing registration-directed trial – – Data from Phase 2 trial of tipifarnib in AITL accepted...